Retinoblastoma RB94 enhances radiation Treatment of head and neck squamous cell carcinoma

Koji Araki, Sidrah M. Ahmad, Guoyan Li, David A. Bray, Koichiro Saito, Daiyou Wang, Uwe Wirtz, Sunil Sreedharan, Bert W. O'Malley, Daqing Li

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To assess whether adenovirus-mediated retinoblastoma 94 (Ad-RB94) transgene expression enhances efficacy of radiation therapy (XRT) of human head and neck squamous cell carcinoma (HNSCC). Experimental Design: The HNSCC cell lines (JHU006 and JHU012) were treated in vitro and in a nude mouse xenograft model with Ad-RB94, Ad-DL312 control vector, or untreated as mock control. Cell viability and tumor growth were evaluated and combined RB94/XRTantitumor activity was analyzed by measuring DNA double-strand breaks, apoptosis-associated early DNA fragmentation, and levels of RB-regulated cell cycle progression E2F1 transcription factor. Results: Ad-RB94/XRTresulted in significant HNSCC cell growth inhibition compared with XRT alone or Ad-RB94 alone in vitro and caused significant tumor regression compared with XRT alone and Ad-DL312/XRT in JHU006 and with XRTalone, Ad-DL312/XRTand Ad-RB94 alone in JHU012 in vivo. Neutral comet analysis revealed that DNA damage was significantly elevated in cells treated with Ad-RB94 alone and Ad-RB94/XRT. Tumors treated with Ad-RB94 alone showed a striking increase in early apoptosis DNA fragmentation, and DNA fragmentation was further enhanced with XRT. In addition, levels of E2F1 were up-regulated by Ad-RB94/XRT combination, whereas Ad-RB94 alone did not affect E2F1 levels and XRT alone led to down-regulation of E2F1. Conclusions: A potent antitumor effect has been observed after Ad-RB94/XRT combination treatment in HNSCC xenograft tumors. Enhanced tumor regression correlated with increased apoptosis. Ad-RB94 treatment enhances the efficacy of XRT through tumor cell sensitization by arresting the cells at the radiation-sensitive G2-M cell cycle and via E2F1 up-regulation.

Original languageEnglish
Pages (from-to)3514-3519
Number of pages6
JournalClinical Cancer Research
Volume14
Issue number11
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Retinoblastoma
Adenoviridae
Radiation
DNA Fragmentation
Therapeutics
Neoplasms
Apoptosis
Heterografts
Carcinoma, squamous cell of head and neck
Cell Cycle
E2F1 Transcription Factor
Double-Stranded DNA Breaks
Growth
Transgenes
Nude Mice
DNA Damage
Cell Survival
Research Design
Up-Regulation
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Araki, K., Ahmad, S. M., Li, G., Bray, D. A., Saito, K., Wang, D., ... Li, D. (2008). Retinoblastoma RB94 enhances radiation Treatment of head and neck squamous cell carcinoma. Clinical Cancer Research, 14(11), 3514-3519. https://doi.org/10.1158/1078-0432.CCR-07-4538

Retinoblastoma RB94 enhances radiation Treatment of head and neck squamous cell carcinoma. / Araki, Koji; Ahmad, Sidrah M.; Li, Guoyan; Bray, David A.; Saito, Koichiro; Wang, Daiyou; Wirtz, Uwe; Sreedharan, Sunil; O'Malley, Bert W.; Li, Daqing.

In: Clinical Cancer Research, Vol. 14, No. 11, 01.06.2008, p. 3514-3519.

Research output: Contribution to journalArticle

Araki, K, Ahmad, SM, Li, G, Bray, DA, Saito, K, Wang, D, Wirtz, U, Sreedharan, S, O'Malley, BW & Li, D 2008, 'Retinoblastoma RB94 enhances radiation Treatment of head and neck squamous cell carcinoma', Clinical Cancer Research, vol. 14, no. 11, pp. 3514-3519. https://doi.org/10.1158/1078-0432.CCR-07-4538
Araki, Koji ; Ahmad, Sidrah M. ; Li, Guoyan ; Bray, David A. ; Saito, Koichiro ; Wang, Daiyou ; Wirtz, Uwe ; Sreedharan, Sunil ; O'Malley, Bert W. ; Li, Daqing. / Retinoblastoma RB94 enhances radiation Treatment of head and neck squamous cell carcinoma. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 11. pp. 3514-3519.
@article{987ae6344d6a40e19aca1b9f3ea34912,
title = "Retinoblastoma RB94 enhances radiation Treatment of head and neck squamous cell carcinoma",
abstract = "Purpose: To assess whether adenovirus-mediated retinoblastoma 94 (Ad-RB94) transgene expression enhances efficacy of radiation therapy (XRT) of human head and neck squamous cell carcinoma (HNSCC). Experimental Design: The HNSCC cell lines (JHU006 and JHU012) were treated in vitro and in a nude mouse xenograft model with Ad-RB94, Ad-DL312 control vector, or untreated as mock control. Cell viability and tumor growth were evaluated and combined RB94/XRTantitumor activity was analyzed by measuring DNA double-strand breaks, apoptosis-associated early DNA fragmentation, and levels of RB-regulated cell cycle progression E2F1 transcription factor. Results: Ad-RB94/XRTresulted in significant HNSCC cell growth inhibition compared with XRT alone or Ad-RB94 alone in vitro and caused significant tumor regression compared with XRT alone and Ad-DL312/XRT in JHU006 and with XRTalone, Ad-DL312/XRTand Ad-RB94 alone in JHU012 in vivo. Neutral comet analysis revealed that DNA damage was significantly elevated in cells treated with Ad-RB94 alone and Ad-RB94/XRT. Tumors treated with Ad-RB94 alone showed a striking increase in early apoptosis DNA fragmentation, and DNA fragmentation was further enhanced with XRT. In addition, levels of E2F1 were up-regulated by Ad-RB94/XRT combination, whereas Ad-RB94 alone did not affect E2F1 levels and XRT alone led to down-regulation of E2F1. Conclusions: A potent antitumor effect has been observed after Ad-RB94/XRT combination treatment in HNSCC xenograft tumors. Enhanced tumor regression correlated with increased apoptosis. Ad-RB94 treatment enhances the efficacy of XRT through tumor cell sensitization by arresting the cells at the radiation-sensitive G2-M cell cycle and via E2F1 up-regulation.",
author = "Koji Araki and Ahmad, {Sidrah M.} and Guoyan Li and Bray, {David A.} and Koichiro Saito and Daiyou Wang and Uwe Wirtz and Sunil Sreedharan and O'Malley, {Bert W.} and Daqing Li",
year = "2008",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-07-4538",
language = "English",
volume = "14",
pages = "3514--3519",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Retinoblastoma RB94 enhances radiation Treatment of head and neck squamous cell carcinoma

AU - Araki, Koji

AU - Ahmad, Sidrah M.

AU - Li, Guoyan

AU - Bray, David A.

AU - Saito, Koichiro

AU - Wang, Daiyou

AU - Wirtz, Uwe

AU - Sreedharan, Sunil

AU - O'Malley, Bert W.

AU - Li, Daqing

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: To assess whether adenovirus-mediated retinoblastoma 94 (Ad-RB94) transgene expression enhances efficacy of radiation therapy (XRT) of human head and neck squamous cell carcinoma (HNSCC). Experimental Design: The HNSCC cell lines (JHU006 and JHU012) were treated in vitro and in a nude mouse xenograft model with Ad-RB94, Ad-DL312 control vector, or untreated as mock control. Cell viability and tumor growth were evaluated and combined RB94/XRTantitumor activity was analyzed by measuring DNA double-strand breaks, apoptosis-associated early DNA fragmentation, and levels of RB-regulated cell cycle progression E2F1 transcription factor. Results: Ad-RB94/XRTresulted in significant HNSCC cell growth inhibition compared with XRT alone or Ad-RB94 alone in vitro and caused significant tumor regression compared with XRT alone and Ad-DL312/XRT in JHU006 and with XRTalone, Ad-DL312/XRTand Ad-RB94 alone in JHU012 in vivo. Neutral comet analysis revealed that DNA damage was significantly elevated in cells treated with Ad-RB94 alone and Ad-RB94/XRT. Tumors treated with Ad-RB94 alone showed a striking increase in early apoptosis DNA fragmentation, and DNA fragmentation was further enhanced with XRT. In addition, levels of E2F1 were up-regulated by Ad-RB94/XRT combination, whereas Ad-RB94 alone did not affect E2F1 levels and XRT alone led to down-regulation of E2F1. Conclusions: A potent antitumor effect has been observed after Ad-RB94/XRT combination treatment in HNSCC xenograft tumors. Enhanced tumor regression correlated with increased apoptosis. Ad-RB94 treatment enhances the efficacy of XRT through tumor cell sensitization by arresting the cells at the radiation-sensitive G2-M cell cycle and via E2F1 up-regulation.

AB - Purpose: To assess whether adenovirus-mediated retinoblastoma 94 (Ad-RB94) transgene expression enhances efficacy of radiation therapy (XRT) of human head and neck squamous cell carcinoma (HNSCC). Experimental Design: The HNSCC cell lines (JHU006 and JHU012) were treated in vitro and in a nude mouse xenograft model with Ad-RB94, Ad-DL312 control vector, or untreated as mock control. Cell viability and tumor growth were evaluated and combined RB94/XRTantitumor activity was analyzed by measuring DNA double-strand breaks, apoptosis-associated early DNA fragmentation, and levels of RB-regulated cell cycle progression E2F1 transcription factor. Results: Ad-RB94/XRTresulted in significant HNSCC cell growth inhibition compared with XRT alone or Ad-RB94 alone in vitro and caused significant tumor regression compared with XRT alone and Ad-DL312/XRT in JHU006 and with XRTalone, Ad-DL312/XRTand Ad-RB94 alone in JHU012 in vivo. Neutral comet analysis revealed that DNA damage was significantly elevated in cells treated with Ad-RB94 alone and Ad-RB94/XRT. Tumors treated with Ad-RB94 alone showed a striking increase in early apoptosis DNA fragmentation, and DNA fragmentation was further enhanced with XRT. In addition, levels of E2F1 were up-regulated by Ad-RB94/XRT combination, whereas Ad-RB94 alone did not affect E2F1 levels and XRT alone led to down-regulation of E2F1. Conclusions: A potent antitumor effect has been observed after Ad-RB94/XRT combination treatment in HNSCC xenograft tumors. Enhanced tumor regression correlated with increased apoptosis. Ad-RB94 treatment enhances the efficacy of XRT through tumor cell sensitization by arresting the cells at the radiation-sensitive G2-M cell cycle and via E2F1 up-regulation.

UR - http://www.scopus.com/inward/record.url?scp=50349083305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349083305&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4538

DO - 10.1158/1078-0432.CCR-07-4538

M3 - Article

C2 - 18519784

AN - SCOPUS:50349083305

VL - 14

SP - 3514

EP - 3519

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -